Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 5/20 | 0.47 |
| ▸ | MEP1A | Q16819 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135982 | 0.89 | GLS (0.46) | MEN1KMT2AGLSAOC3HTR2C | |
| SCHEMBL3010698 | 0.86 | MRGPRX4 (0.45) | MEN1KMT2AHTR2CSLC6A4FOLH1 | |
| SCHEMBL1830055 | 0.86 | LOXL2 (0.54) | MEN1KMT2AGLSHTR2CSLC6A4 | |
| SCHEMBL29580473 | 0.86 | MRGPRX4 (0.45) | MEN1KMT2AHTR2CSLC6A4FOLH1 | |
| SCHEMBL20794226 | 0.84 | MEP1B (0.54) | MEN1KMT2AAOC3MEP1BMEP1A | |
| SCHEMBL7190668 | 0.84 | RIPK1 (0.57) | MEN1KMT2AGLSHTR2CSLC6A4 | |
| SCHEMBL14987121 | 0.83 | GLS (0.56) | MEN1KMT2AGLSAOC3HTR2C | |
| SCHEMBL21561867 | 0.83 | HTR2C (0.44) | MEN1KMT2AGLSAOC3HTR2C | |
| SCHEMBL7021352 | 0.83 | GLS (0.53) | MEN1KMT2AGLSAOC3HTR2C | |
| SCHEMBL1831339 | 0.83 | GLS (0.50) | MEN1KMT2AGLSAOC3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| CN-1227230-C | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | CN | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| CN-1447793-A | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2003-10-08 | — | — | CN | disclosed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
| US-5578629-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996030015-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5534537-A | Prodrugs of inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | MEN1 1089/4885KMT2A 1763/4885GLS 2986/4885 |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | MEN1 4382/4885KMT2A 2738/4885GLS 879/4885 |
| US-20080255109-A1 | Non-peptide GnRH antagonists | GNRHR, BRS3, FSHR | MEN1 1037/4885KMT2A 1744/4885GLS 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.